$FEMY SEC Filings

Filed On	Filing
15 Oct 2026	SCHEDULE 13G
29 Sep 2026	424B3
28 Sep 2026	EFFECT
03 Sep 2026	S-3
31 Aug 2026	SCHEDULE 13G
20 Aug 2026	D
17 Aug 2026	SCHEDULE 13D
14 Aug 2026	10-Q
14 Aug 2026	SCHEDULE 13G
14 Aug 2026	8-K: Results of Operations and Financial Condition
11 Aug 2026	Form 4: Eichenbaum Kenneth D., Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Uzialko Edward R, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Milnes Alistair, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Larsen Charles, Director Granted 880 Stock Option (Right to Buy)
11 Aug 2026	Form 4: Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs Bought 3,125 shares ($10K) · Granted 3,125 Common Stock Purchase Warrant · Granted 3,125 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs Granted 6,250 Stock Option (Right to Buy)
11 Aug 2026	Form 3: Mifek Jeffrey Gerald, Chief Clinical-Medical Affairs Holds 1,411 shares of Common Stock
11 Aug 2026	Form 4: Sipos Jeremy Alexander, Chief Technology Officer Bought 3,125 shares ($10K) · Granted 3,125 Common Stock Purchase Warrant · Granted 3,125 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Canning John Charles, Chief Operating Officer Bought 4,375 shares ($14K) · Granted 4,375 Common Stock Purchase Warrant · Granted 4,375 Common Stock Purchase Warrant (Milestone)
11 Aug 2026	Form 4: Elefant Dov, Chief Financial Officer Bought 15,625 shares ($50K) · Granted 15,625 Common Stock Purchase Warrant · Granted 15,625 Common Stock Purchase Warrant (Milestone)

Comments